Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedCore content updated to reflect funding-related operational notices and new version v3.2.0; previous v3.1.0 version removed.SummaryDifference0.9% 
- Check32 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.0% 
- Check47 days agoChange DetectedUpdated version from v3.0.1 to v3.0.2; removed the 'Back to Top' element. Overall, the substantive content remains the same aside from the version update.SummaryDifference0.1% 
- Check54 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1% 
- Check61 days agoChange DetectedThe web page has undergone significant updates, including the addition of new facility names and locations, as well as updated drug information for tepotinib and osimertinib. Notably, the page has removed some previous location details and drug information, indicating a refinement in the content presented.SummaryDifference10% 
- Check76 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0% 
Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.